Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Neurology. 2008 May 28;70(24):2291–2298. doi: 10.1212/01.wnl.0000313933.17796.f6

Table 4.

Adjusted HRs for various categorizations of NSAID use

N PY AD aHR (95% CI)
Model 1*
  No NSAID 9,501 47,293 642 1.0
  SALA alone 2,544 14,828 127 0.82 (0.67 – 0.99)
  Non-SALA alone 743 4,162 25 0.60 (0.40 – 0.90)
  Both SALA & non-SALA 573 3,704 23 0.87 (0.57 – 1.33)
  Unclassifiable alone 96 556 3 0.61 (0.19 – 1.89)

Model 2*
  No NSAID 9,501 47,293 642 1.0
  Any ibuprofen 2,093 12,731 103 0.88 (0.71 – 1.09)
  Other than ibuprofen 1,863 10,518 75 0.67 (0.53 – 0.86)

Model 3*
  No NSAID 9,501 47,293 642 1.0
  Any naproxen 806 4,887 22 0.55 (0.36 – 0.85)
  Other than naproxen 3,150 18,363 156 0.82 (0.69 – 0.99)

aHR=adjusted hazard ratio, N=number, PY=person years, AD=incident Alzheimer’s dementia, CI=confidence interval, NSAID=non-steroidal anti-inflammatory drug, SALA=selective Aβ42-lowering agent

Each model shows the relationship between a medication classification and the risk of incident AD. All models are stratified by study and adjusted for age, sex, and education. The variables shown within each model are mutually exclusive categorizations of the medication exposure of interest.

*

Data on NSAID type missing for 42 participants